291 related articles for article (PubMed ID: 22973562)
1. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
Hanif SN; Garcia-Contreras L
Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
[TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
3. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
Garcia-Contreras L; Sung JC; Muttil P; Padilla D; Telko M; Verberkmoes JL; Elbert KJ; Hickey AJ; Edwards DA
Antimicrob Agents Chemother; 2010 Apr; 54(4):1436-42. PubMed ID: 20086154
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
5. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
6. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
8. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
9. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
10. Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate.
Gomez M; McCollum J; Wang H; Ordoubadi M; Jar C; Carrigy NB; Barona D; Tetreau I; Archer M; Gerhardt A; Press C; Fox CB; Kramer RM; Vehring R
Int J Pharm; 2021 Jan; 593():120121. PubMed ID: 33278492
[TBL] [Abstract][Full Text] [Related]
11. A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.
Pitner RA; Durham PG; Stewart IE; Reed SG; Cassell GH; Hickey AJ; Carter D
J Pharm Sci; 2019 Oct; 108(10):3302-3311. PubMed ID: 31152746
[TBL] [Abstract][Full Text] [Related]
12. Spray drying TB vaccines for pulmonary administration.
Fourie PB; Germishuizen WA; Wong YL; Edwards DA
Expert Opin Biol Ther; 2008 Jul; 8(7):857-63. PubMed ID: 18564902
[TBL] [Abstract][Full Text] [Related]
13. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
[TBL] [Abstract][Full Text] [Related]
14. Dry powder pharmaceutical biologics for inhalation therapy.
Chang RYK; Chow MYT; Khanal D; Chen D; Chan HK
Adv Drug Deliv Rev; 2021 May; 172():64-79. PubMed ID: 33705876
[TBL] [Abstract][Full Text] [Related]
15. Uniformity and Efficacy of Dry Powders Delivered to the Lungs of a Mycobacterial-Surrogate Rat Model of Tuberculosis.
Hirota K; Hirai Y; Nakajima T; Goto S; Makino K; Terada H
Pharm Res; 2022 Jan; 39(1):143-152. PubMed ID: 34950976
[TBL] [Abstract][Full Text] [Related]
16. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Momin MAM; Tucker IG; Das SC
Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
18. A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment.
Patil SM; Diorio AM; Kommarajula P; Kunda NK
Int J Pharm; 2024 Mar; 653():123920. PubMed ID: 38387819
[TBL] [Abstract][Full Text] [Related]
19. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
20. The role of particle properties in pharmaceutical powder inhalation formulations.
Chew NY; Chan HK
J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
